Dr Susan Galbraith at ESMO 2014: Phase I/II AURA study of the EGFR inhibitor, AZD9291, in advanced NSCLC

Dr Susan Galbraith at ESMO 2014: Phase I/II AURA study of the EGFR inhibitor, AZD9291, in advanced NSCLC

User Photo
EMJ

6 years
1,184 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ongoing phase I/II AURA study of the epidermal growth factor receptor (EGFR) inhibitor, AZD9291, in patients with advanced non-small cell lung cancer (NSCLC) and disease progression while on a previous continuous treatment with an EGFR inhibitor.
Up Next Autoplay
>